Your browser doesn't support javascript.
loading
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
Li, C H; Bies, R R; Wang, Y; Sharma, M R; Karovic, S; Werk, L; Edelman, M J; Miller, A A; Vokes, E E; Oto, A; Ratain, M J; Schwartz, L H; Maitland, M L.
Afiliação
  • Li CH; Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Bies RR; Indiana Clinical and Translational Sciences Institute (CTSI), Indianapolis, Indiana, USA.
  • Wang Y; Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Sharma MR; Indiana Clinical and Translational Sciences Institute (CTSI), Indianapolis, Indiana, USA.
  • Karovic S; Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.
  • Werk L; Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Edelman MJ; Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.
  • Miller AA; University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
  • Vokes EE; University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
  • Oto A; Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.
  • Ratain MJ; Duke University, Durham, North Carolina, USA.
  • Schwartz LH; Alliance for Clinical Trials in Oncology, Boston, Massachusetts, USA.
  • Maitland ML; University of Maryland Greenebaum Cancer Center, School of Medicine, Baltimore, Maryland, USA.
Clin Transl Sci ; 9(1): 43-50, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26790562
Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tomografia Computadorizada por Raios X / Determinação de Ponto Final / Critérios de Avaliação de Resposta em Tumores Sólidos / Modelos Biológicos / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tomografia Computadorizada por Raios X / Determinação de Ponto Final / Critérios de Avaliação de Resposta em Tumores Sólidos / Modelos Biológicos / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article